Drug intelligence / Profile preview

AD-2131

Development stage: Preclinical
Lead developer: Addpharma

Overview

AD-2131 is an investigational drug developed by Addpharma, primarily targeting digestive system disorders. Its current global highest R&D status is listed as "Pending," and it has been the subject of clinical studies comparing its safety, pharmacokinetics, and pharmacodynamics to a related compound (AD-213-A) in healthy volunteers. Specific details regarding its mechanism of action, molecular target(s), or chemical class have not been disclosed in publicly available sources[1][2][3][5].

Beyond the preview

Go deeper on AD-2131.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-2131.

Explore the full profile